Desviando a resistência aos antibióticos pela redução da evolução bacteriana

segunda-feira, novembro 19, 2018

Inhibiting the Evolution of Antibiotic Resistance

Mark N. Ragheb 1 2 Maureen K. Thomason 1 Chris Hsu 1 Patrick Nugent 1 John Gage 1 Ariana N. Samadpour 1 Ankunda Kariisa 1Christopher N. Merrikh 1 Samuel I. Miller 1 3 David R. Sherman 4 5 Houra Merrikh 1 3 6

Department of Microbiology, University of Washington, Seattle, WA, USA

Molecular and Cellular Biology Graduate Program and Medical Scientist Training Program, University of Washington, Seattle, WA, USA

Department of Genome Sciences, University of Washington, Seattle, WA, USA

Center for Infectious Disease Research, Seattle, WA, USA

Interdiscipinary Program of Pathobiology, Department of Global Health, University of Washington, Seattle, WA, USA

Received 15 June 2018, Revised 17 August 2018, Accepted 9 October 2018, Available online 15 November 2018.

Published: November 15, 2018

Under a Creative Commons license open access


• The bacterial transcription-coupled repair (TCR) factor Mfd promotes mutagenesis

• Mfd-driven mutagenesis accelerates the evolution of antimicrobial resistance (AMR)

• The rapid evolution of AMR requires Mfd’s interaction with RpoB and UvrA

• Mfd may be an ideal target for “anti-evolution” drugs that inhibit AMR development


Efforts to battle antimicrobial resistance (AMR) are generally focused on developing novel antibiotics. However, history shows that resistance arises regardless of the nature or potency of new drugs. Here, we propose and provide evidence for an alternate strategy to resolve this problem: inhibiting evolution. We determined that the DNA translocase Mfd is an “evolvability factor” that promotes mutagenesis and is required for rapid resistance development to all antibiotics tested across highly divergent bacterial species. Importantly, hypermutator alleles that accelerate AMR development did not arise without Mfd, at least during evolution of trimethoprim resistance. We also show that Mfd’s role in AMR development depends on its interactions with the RNA polymerase subunit RpoB and the nucleotide excision repair protein UvrA. Our findings suggest that AMR development can be inhibited through inactivation of evolvability factors (potentially with “anti-evolution” drugs)—in particular, Mfd—providing an unexplored route toward battling the AMR crisis.

FREE PDF GRATIS: Molecular Cell